SCYX insider trading
NasdaqCM HealthcareSCYNEXIS INC: insider trade history from SEC Form 4 filings.
About SCYNEXIS INC
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, CJSC (R-Pharm), and Cypralis Limited for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Company website: www.scynexis.com
SCYX insider activity at a glance
FilingIQ tracks 129 insider transactions for SCYX in filings since Aug 27, 2015. The most recent transaction is dated Sep 18, 2026.
Across the full history, 63 open-market purchases
and 4 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on SCYX insider trades is 55.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest SCYX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for SCYX?
- FilingIQ tracks 129 Form 4 insider transactions for SCYX (SCYNEXIS INC), covering filings from Aug 27, 2015 onwards. 1 of those are dated within the last 90 days.
- Are SCYX insiders net buyers or net sellers?
- Across the full Form 4 history for SCYX, 63 transactions (49%) were open-market purchases and 4 (3%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does SCYX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is SCYX in?
- SCYNEXIS INC (SCYX) is classified in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a current market capitalisation of $32.49M.
Methodology & sources
Every SCYX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.